Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03904498
PHASE2

COMT Inhibition Among Individuals With Comorbid AUD/ADHD

Sponsor: University of Colorado, Denver

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether the catechol-O-methyltransferase (COMT) inhibitor tolcapone, relative to placebo, affects response to alcohol, decision-making, brain activation associated with alcohol cue reactivity, response inhibition, and selective attention, or alcohol drinking.

Official title: COMT Inhibition as a Potential Therapeutic Target Among Individuals With Comorbid Alcohol Use Disorder and Attention-Deficit/Hyperactivity Disorder

Key Details

Gender

All

Age Range

21 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

62

Start Date

2021-08-16

Completion Date

2025-03-01

Last Updated

2024-11-25

Healthy Volunteers

No

Interventions

DRUG

Tolcapone

Tolcapone 100 mg tablets

DRUG

Placebo

Placebo tablets

Locations (1)

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States